



Dear Shareholder,

With the recent launch of the AsthmaSense™ v1.0 smartphone app for asthma management, the Company has taken a decisive step toward its long range vision of building a profitable business based on mobile health technology and Acoustic Respiratory Monitoring (ARM™) devices.

The Board is now seeking shareholder support on three resolutions that will facilitate continued progress toward these commercialisation goals.

The General Meeting of Shareholders will be held at 11:00 am on 27 July 2012 at Suite 1, 1233 High Street, Armadale, Victoria. The objectives of this meeting will be to:

- Confirm the appointment of new Directors to the Board,
- Ratify the issue of previous shares and options, and
- Approve the consolidation of share capital (20:1 ratio), the record date to be agreed following Shareholder approval.

Consolidation of iSonea shares is both advisable and necessary at this time. The Board believes that share consolidation will make the Company more attractive to institutional investors and has the potential to reduce administrative costs and to help modulate short-term share price fluctuation.

The importance of mobile health technology as a component of successful disease management is now evident to healthcare providers and stakeholders. Likewise, market analysts are beginning to recognise its impact as a growth engine for the Company and for investors.

Remote monitoring of asthma remains a serious unmet medical need. Harnessing the universally available smartphones will enable iSonea to offer asthma patients cost-effective access to the most innovative monitoring technology available and to improve communication and data sharing with physicians and caregivers.

The continuing evolution of our AsthmaSense app series, with increasingly sophisticated risk-sensing and personal alert features, as well as the ongoing technical development of the SonoSentry™ and AirSonea™ monitoring products, demonstrate that the Company is moving steadily toward the goal of providing patients, families, physicians, and therapy companies with the ultimate "Asthma Operating System" to improve chronic disease management outcomes. As we strive toward this endpoint, the Directors would like to thank the shareholders for their continued support and interest in iSonea.

A handwritten signature in blue ink, appearing to read "Ross Haghghat", is written over a light blue circular stamp.

Ross Haghghat
Executive Chairman

iSonea Limited

Dated: Friday 22nd June 2012